CVAC - Pfizer/BioNTech seek to revoke patent infringement claims by CureVac over COVID vaccine

• German biotech BioNTech ( NASDAQ: BNTX ) and U.S. partner Pfizer ( NYSE: PFE ) have filed proceedings in a high court in England seeking judgement that their blockbuster mRNA-technology based COVID-19 vaccine does not infringe on two of CureVac's ( NASDAQ: CVAC ) European patents.
• The companies filed the proceedings in the Patents Court, High Court of England & Wales, BNTX said in a regulatory filing .
• CureVac ( CVAC ), a local rival to BNTX, in July said it had filed a lawsuit in Germany over the infringement of certain intellectual property rights related to BNTX and PFE's vaccine, called Comirnaty.
• "The COVID-19 vaccine is based on BioNTech’s proprietary mRNA technology and was developed by both BioNTech and Pfizer," BNTX asserted in Friday's filing.
• CVAC had said that it would not seek an injunction or resort to legal action that could disrupt the production and sales of the vaccine.
• Pfizer in late July had said that Comirnaty had added direct sales and alliance revenues worth $8.9B to its overall revenue in Q2.

For further details see: